Publications

Final results from the Phase I study expansion cohort of the selective FGFR inhibitor Debio 1347 in patients with solid…

DEBIO 1347 In Patients With GastroIntestinal Cancers Harboring An FGFR Gene Fusion: Preliminary Results

FUZE Clinical Trial: a Phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of the tumor histology

Molecular screening of patients with FGFR alterations for a phase 1 (Ph1) study with the selective FGFR inhibitor (FGFRi) Debio…

Safety and efficacy of the selective FGFR inhibitor Debio 1347 in phase 1 study patients with fgfr genomically activated advanced…

FGFR selective inhibitor Debio1347 induces tumor regressions in FGFR2-altered gastric cancer PDX models

Mechanism of oncogenic signal activation by the novel fusion kinase FGFR3-BAIAP2L1

Characterization of Two Novel Oncogenic FGFR2 Fusions Sensitive to the FGFR Selective Inhibitor Debio 1347 in Cholangiocarcinoma

First-in-human phase I “basket” study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients with FGFR genomically activated advanced solid…